Stentys starts stent study
This article was originally published in Clinica
Executive Summary
Stentys has enrolled the final patient in its APPOSITION II clinical study, a randomised trial comparing the Stentys self-expanding stent with a conventional balloon-expandable stent in patients with acute myocardial infarction (AMI). The study results will be announced in September. Stentys, which is based in Princeton, New Jersey and Paris, France, CE marked the device for sale in Europe for the treatment of acute coronary syndrome in March (www.clinica.co.uk, 8 March 2010). AMI affects 100,000 people every year in France and 900,000 people in the US.
You may also be interested in...
ITF Has A Fight On Its Hands In Duchenne
The group’s new muscular dystrophy pill seems unlikely to cut into Sarepta’s sales.
AbbVie Needs To Freshen Up
With half of its 2023 sales coming from aging blockbusters like Humira and Botox, AbbVie needs new blood.
AstraZeneca Pays $2bn To Keep Up With The Joneses
Bristol Myers Squibb and Lilly have recently done billion-dollar radiopharmaceuticals deals, and now the UK group wants a piece of the market. But can it make its Fusion fusion work?